Virtual Overdose Response
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04391192|
Recruitment Status : Withdrawn (Sponsor determined that it must be terminated)
First Posted : May 18, 2020
Last Update Posted : May 25, 2021
|Condition or disease||Intervention/treatment||Phase|
|Drug Overdose||Behavioral: Virtual Overdose Response||Not Applicable|
Designed as a small open label clinical study to demonstrate proof of concept which will follow CONSORT guidelines, the investigators aim to recruit approximately 15 people who are currently using illicit substances and who currently use opioids (illicit or prescription - non-medically). The sample size of 15 balances pragmatic issues (difficulty in recruiting people who are actively using illicit substances) and the need to have a good sample of the population. These participants will be interviewed by the research coordinator in person prior to intervention initiation to determine baseline use; history of overdose; and current harm reduction activities (see appendix). They will then be asked to call the intervention number if they are going to be using alone (see appendix for call flow).
Each time a participant dials the number, the operator will gather (as part of the intervention) the address the participant is at, their name/pseudonym and a phone number that can be used as a call back number in case the call is disconnected. The phone line operator will then ask a) what they planned on using, b) the method of use, c) if the participant is using safe sterile supplies (and provide information on where they can get new supplies in their community), and d) if they have a naloxone kit (overdose reversal kit) available. They will then inform the participant that they will be checking in on them every 5 - 10 minutes and if they do not respond, they will call emergency medical services for them.
If the participant responds to each verbal prompt (calling their name) over a minimum of 30 minutes, the operator will let them know that they are disconnecting the call. The operator will offer to connect the participant to other health services, such as the location of new supplies, social services, addiction treatment and opioid agonist therapy. If the participant fails to respond to a prompt (or the call is disconnected and is not able to be reconnected), the operator will contact the dispatch supervisor and the process for emergency services dispatch will be initiated.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Feasibility of using a phone line to provide overdose response.|
|Masking:||None (Open Label)|
|Official Title:||Virtual Overdose Response|
|Estimated Study Start Date :||September 2020|
|Estimated Primary Completion Date :||October 2020|
|Estimated Study Completion Date :||February 2021|
All participants will be given the phone number and encouraged to call any time they plan to use substances alone
Behavioral: Virtual Overdose Response
All participants will be provided the phone number and encouraged to call when they use alone.
- Usage [ Time Frame: 3 months ]Number of times participants call the phone line
- EMS response time [ Time Frame: 3 months ]Amount of time from calling 911 to EMS arriving on scene
- EMS dispatch outcome [ Time Frame: 3 months ]qualitative description of dispatch outcome
- Length of calls [ Time Frame: 3 months ]overall time required for a single call to the service
- Proportion of calls for which EMS is dispatched [ Time Frame: 3 months ]quantitative analysis of the number of times the operator calls 911 for a participant
- Timing of calls [ Time Frame: 3 months ]Analysis of what time of day most calls come in to the service
- Health care usage [ Time Frame: 3 months ]analysis of overall health system usage (based on administrative data) by the participants
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04391192
|Calgary, Alberta, Canada|
|Principal Investigator:||Katherine Rittenbach, PhD||Alberta Health Services|